Cellectis (CLLS)

• Market cap: $506M
• 1 day: -3.82%
• 5 days: 3.7%
• 1 month: 38.84%
• 3 months: 94.59%
• 6 months: 245.21%
• Year to date: 178.45%
• 1 year: 135.51%
• 5 years: -79.18%
• 10 years: -85.23%
• Sector: Healthcare
• Industry: Biotechnology

About: Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

Employees: 222